4558 Investigating the functional consequences of anaplastic lymphoma kinase (ALK) mutations arising upon Lorlatinib treatment
Witek G, Miller W, Slochower D, Berko E, Mossé Y, Lemmon M, Radhakrishnan R. 4558 Investigating the functional consequences of anaplastic lymphoma kinase (ALK) mutations arising upon Lorlatinib treatment. Journal Of Clinical And Translational Science 2020, 4: 9-10. PMCID: PMC8823389, DOI: 10.1017/cts.2020.74.Peer-Reviewed Original ResearchAnaplastic lymphoma kinaseNB patientsALK mutationsMechanisms of resistanceCompound mutationsALK inhibitorsNon-small cell lung cancerLimited anti-tumor activityAnaplastic lymphoma kinase (ALK) mutationsDiverse clinical responsesSympathetic nervous systemCell lung cancerRecent clinical trialsSignificant side effectsDe novo resistanceALK tyrosine kinaseAnti-tumor activityActivation stateNew ALK inhibitorsHereditary neuroblastomaLorlatinib treatmentClinical responseTyrosine kinaseRelapsed neuroblastomaNew immunotherapies